Compound A Kv7 Channel Opening for Refractory Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiseizure medications (ASMs) are ineffective for up to 30% of patients with epilepsy, as they do not adequately target neuronal potassium-gated channels, leading to uncontrolled seizures and a poor quality of life for refractory patients.
Innovation Solution
Conjoint administration of the small molecule Compound A, which enhances the opening of Kv7 potassium channels, with established ASMs like valproic acid, levetiracetam, or phenytoin to reduce seizure frequency and severity, potentially lowering the required doses of these medications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ASMs are used to treat seizure disorders, then seizure control is achieved in some patients, but up to 30% of patients remain refractory with uncontrolled seizures
Solution Approach 1:
The patent combines Compound A (a Kv7.2/Kv7.3 channel opener) with conventional ASMs to create a combination therapy. This merging approach addresses the refractory epilepsy problem by integrating a novel mechanism of action (Kv7 channel opening) with existing treatment regimens, thereby expanding treatment effectiveness across the patient population without completely replacing conventional therapies.
Solution Approach 2:
The patent introduces a new pharmacological parameter - modulation of Kv7.2/Kv7.3 potassium channel activity - to the existing treatment landscape. By changing the therapeutic target from traditional ASM mechanisms to Kv7 channel opening, the invention creates a new dimension of treatment effectiveness that addresses refractory cases that conventional ASMs cannot control.
2Reliability
If higher doses of conventional ASMs are increased to control seizures in refractory patients, then seizure control may improve, but the risk/benefit profile deteriorates and quality of life decreases
Solution Approach 1:
Compound A serves as an intermediary agent that enhances the efficacy of conventional ASMs through synergistic interaction. Rather than simply increasing ASM doses, the patent uses Compound A as a mediator that potentiates the effect of existing ASMs, achieving better seizure control at lower ASM doses and thereby reducing adverse effects and improving quality of life.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining Compound A with conventional ASMs in a single treatment regimen. This composite therapy leverages the complementary mechanisms of action - Kv7 channel opening by Compound A and traditional ASM mechanisms - to achieve superior seizure control with a more favorable safety profile compared to high-dose ASM monotherapy.
3Reliability
If current ASMs are used to treat epilepsy, then some therapeutic effect is achieved, but neuronal potassium-gated channels are not adequately targeted
Solution Approach 1:
The patent creates a multi-functional treatment approach where Compound A specifically targets Kv7.2/Kv7.3 potassium channels, adding this specific mechanism to the existing ASM arsenal. This universality principle allows the combination therapy to address multiple seizure mechanisms simultaneously - both the traditional ASM mechanisms and the Kv7 channel modulation - thereby expanding overall mechanism coverage and therapeutic versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of Compound A with ASMs demonstrates additive or synergistic effects, providing improved efficacy in reducing seizure episodes and severity, potentially stabilizing neuronal excitability and reducing the need for higher doses of conventional ASMs.
Implementation Method 1
Compound A is a small molecule that enhances the opening of voltage-gated potassium channels, particularly Kv7.2 and Kv7.3 channels, in neurons. This enhancement hyperpolarizes the cell membrane and reduces neuronal excitability, thereby preventing the initiation and propagation of action potential bursts that manifest as epileptic seizures.
Data Source
AI summary
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human in need thereof, wherein the methods and uses comprise conjointly administering N44-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyll-3,3-dimethylbutanamide (Compound A) and an antiseizure medication (ASM) to the human in amounts that are therapeutically effective when conjointly administered. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.